No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:06:45.731Z. Latest historical point 2024-05-14. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Gain Therapeutics, Inc. (GANX) stock was $1.73 as of Oct 6, 2026, 11:05 AM EDT, up 2.63% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -11.9% · 3-year avg -19.3%/yr · 5-year avg -25.1%/yr
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins.
Biotechnology · Bethesda, MD
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.13
Revenue Est.
$33333.00
Last Quarter Results
EPS
$-0.11
vs Estimate
$-0.15
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GANX | $73.98M | $1.73 | +2.63% | -11.93% | -25.06% | N/A | N/A |
| 2HYPR | $76.00M | $0.90 | +2.22% | -40.20% | -38.34% | N/A | vs GANX |
| 3HYFT | $70.95M | $1.51 | +1.34% | -11.78% | -23.93% | N/A | vs GANX |
| 4IBIO | $70.74M | $1.10 | -1.79% | +30.14% | -70.43% | -54.11% | vs GANX |
| 5NTHI | $77.28M | $2.98 | +2.05% | -74.51% | N/A | N/A | vs GANX |
| 6OM | $77.30M | $4.17 | +1.71% | -71.53% | -64.47% | N/A | vs GANX |
forward FY estimate
N/A
$0.00
vs Estimate
$33333.00
Consensus Rating
Based on 5 analysts
Average Price Target
$7.20
+315.1% upside
Low
$5.00
Current
$1.73
High
$8.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.12 | $-0.12 | $-0.12 | 3 |
| Quarter ending Dec 2026 | $-0.15 | $-0.13 | $-0.11 | 3 |
| Quarter ending Mar 2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Quarter ending Jun 2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.52 | $-0.50 | $-0.48 | 3 |
| FY 2027 | $-0.77 | $-0.65 | $-0.58 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $33333.00 | $33333.00 | $33333.00 | 2 |
| Quarter ending Dec 2026 | $33333.00 | $33333.00 | $33333.00 | 2 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $50000.00 | $50000.00 | $50000.00 | 4 |
| FY 2027 | $225000.00 | $225000.00 | $225000.00 | 5 |
